Table 2 Frequency of and time to HAART associated toxic complications by initiating regimen
Condition | Stavudine (N = 8497) | Other drugs (N = 543) |
|---|---|---|
Peripheral neuropathy | Â | Â |
Frequency | 1454 (17.1)* | 61 (11.2)* |
Time to diagnosis | 6.7 (3.8-111.8) | 5.1 (3.1-11.7) |
Symptomatic hyperlactataemia | Â | Â |
Frequency | 487 (5.7)* | 12 (2.2)* |
Time to diagnosis | 14.5 (10.6-20.9) | 11.6 (8.7-19.4) |
Lactic Acidosis | Â | Â |
Frequency | 214 (2.5) | 7 (1.3) |
Time to diagnosis | 10.8 (9.0-13.5) | 11.2 (9.0-13.5) |
Pancreatitis | Â | Â |
Frequency | 14 (0.2) | 1 (0.2) |
Time to diagnosis | 10.4(4.0-13.0) | 8.3 (8.3-8.3) |
Lipoatrophy | Â | Â |
Frequency | 616 (7.3)** | 25 (4.6) ** |
Time to diagnosis | 17.0 (11.4-23.1) | 15.0 (10.5-24.8) |
Hypertension | Â | Â |
Frequency | 167 (2.0) | 9.7 (4.6-18.4)** |
Time to diagnosis | 17 (3.1) | (9.3-30.5)** |
Diabetes | Â | Â |
Frequency | 28 (0.3) | 1 (0.2) |
Time to diagnosis | 22.4 (12.5-28.1) | 9.0 (9.0-9.0) |
Dyslipidaemia | Â | Â |
Frequency | 109 (1.3) | 9(1.7) |
Time to diagnosis | 24.6 (17.4-34.0) | 19.1 (15.3-26.1) |